Compounds > rosenthal's inhibitor
Page last updated: 2024-12-08

rosenthal's inhibitor

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Rosenthal's inhibitor: RN given refers to acetate salt; inhibits phopholipases A1 and A2 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID160880
SCHEMBL ID7453596
MeSH IDM0064239

Synonyms (23)

Synonym
rosenthal's inhibitor
7059-39-4
n-(2-hydroxyethyl)-n,n-dimethyl-2,3-bis(octadecanoyloxy)propan-1-aminium acetate
niosh/bp8243850
dl-2,3-distearoyloxypropyl(dimethyl)-beta-hydroxyethylammonium acetate
ammonium, (2,3-dihydroxypropyl)dimethyl(2-hydroxyethyl)-, acetate, distearate, dl-
BP82438500
dimethyl dl-2,3-distearoyloxypropyl-2'-hydroxyethylammonium acetate
1-propanaminium, n-(2-hydroxyethyl)-n,n-dimethyl-2,3-bis((1-oxooctadecyl)oxy)-, acetate (salt)
(2,3-dihydroxypropyl)(2-hydroxyethyl)dimethylammonium distearate acetate
dimethyl-dl-2,3-distearoyloxypropyl-2'-hydroxyethylammonium acetate
dimethyl-2,3-distearolyoxypropyl-2'-hydroxylethylammonium acetate
1-propanaminium, n-(2-hydroxyethyl)-n,n-dimethyl-2,3-bis((1-oxooctadecyl)oxy)-, (+-)-, acetate (salt)
13106-14-4
dds-acetate
dimethyl-dl-2,3-distearoyloxypropyl(2-hydroxyethyl)ammonium acetate
SCHEMBL7453596
DTXSID10276491
106545-38-4
J-005929
2,3-di(octadecanoyloxy)propyl-(2-hydroxyethyl)-dimethylazanium;acetate
1-propanaminium, n-(2-hydroxyethyl)-n,n-dimethyl-2,3-bis[(1-oxooctadecyl)oxy]-, acetate (1:1)
n-(2-hydroxyethyl)-n,n-dimethyl-2,3-bis(stearoyloxy)propan-1-aminium acetate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (40.00)18.7374
1990's2 (20.00)18.2507
2000's3 (30.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.92 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
quinacrine
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.		2.3720acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
gallic acid
gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.		1.9610trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
carmustine
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.		1.9610N-nitrosoureas;
organochlorine compound		alkylating agent;
antineoplastic agent
tetracaine
Tetracaine: A potent local anesthetic of the ester type used for surface and spinal anesthesia.. tetracaine : A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia.		1.9610benzoate ester;
tertiary amino compound		local anaesthetic
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate
8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate: intracellular calcium antagonist; RN given refers to parent cpd		1.9610trihydroxybenzoic acid
edetic acid
Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.		2.3920ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid		anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector
sepharose
agarose : A linear polysaccharide made up from alternating D-galactose and 3,6-anhydro-alpha-L-galactopyranose residues joined by alpha-(1->3)- and beta-(1->4)-linkages.		1.9710
phosphatidylcholines
Phosphatidylcholines: Derivatives of PHOSPHATIDIC ACIDS in which the phosphoric acid is bound in ester linkage to a CHOLINE moiety.		2.66301,2-diacyl-sn-glycero-3-phosphocholine
stearates
Stearates: Salts and esters of the 18-carbon saturated, monocarboxylic acid--stearic acid.		3.69100
ConditionIndicatedRelationship StrengthStudiesTrials
Allergic Encephalomyelitis
[description not available]		02.0610
MS (Multiple Sclerosis)
[description not available]		02.0610
Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)		02.0610
Extravascular Hemolysis
[description not available]		02.4220
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		02.4220
African Lymphoma
[description not available]		01.9610
Autosomal Recessive Chronic Granulomatous Disease
[description not available]		01.9610
Burkitt Lymphoma
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.		01.9610
Granulomatous Disease, Chronic
A defect of leukocyte function in which phagocytic cells ingest but fail to digest bacteria, resulting in recurring bacterial infections with granuloma formation. When chronic granulomatous disease is caused by mutations in the CYBB gene, the condition is inherited in an X-linked recessive pattern. When chronic granulomatous disease is caused by CYBA, NCF1, NCF2, or NCF4 gene mutations, the condition is inherited in an autosomal recessive pattern.		01.9610